ijms-logo

Journal Browser

Journal Browser

Molecular Advances in Pathology, Diagnosis and Treatment of Gynaecological Cancers

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1184

Special Issue Editors


E-Mail Website
Guest Editor
Department of Oncology, University of Turin, Medical Oncology, Ordine Mauriziano Hospital, Turin, Italy
Interests: targeted therapies in gynaecological cancer; PARP inhibitors in ovarian cancer; clinical trials in gynaecological cancer
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
Interests: prostate cancer,kidney cancer; ovarian cancer; mismatch repair; endometrial cancer; castration resistant prostate cancer; tumor-infiltrating lymphocytes; PARP inhibitors; gynecological malignancies; DNA repair deficiencies; BRCA alteration
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

In recent years, new insights, novel developments, latest discoveries, and future challenges radically changed the field of gynecologic oncology. According to the tumor origin, gynecologic malignancies are mainly classified into ovarian cancer (epithelial, germ cell tumor, sexual-stromal tumor, and others), endometrial cancer, cervical cancer, and vulvar cancer, which are recognized as global health threats for women.

In the past decades, multimodal strategies consisting of surgery, radiation, and chemotherapy were the main choices for these patients with gynecologic malignancies. This research topic aims to provide updates on the newly identified molecular targets and developed therapeutic strategies for gynecological cancers, and to discuss the recent advances on the screening, diagnosis, therapies, and prognosis of gynecological cancers. We welcome submissions of articles which provide novel information in the fields encompassing, but not limited to, the identifications of cancer signaling pathways, potential therapeutic target discoveries, the development of new targeted drugs, and therapeutic strategies for gynecological cancers. The submitted articles in this research topic will help to highlight the current knowledge and trends regarding the targeted therapy of gynecological cancers.

Dr. Valentina Tuninetti
Dr. Alberto Farolfi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted therapy
  • precision medicine
  • predictive factors
  • molecular classification
  • ovarian cancer
  • endometrial cancer
  • cervical cancer

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 544 KiB  
Review
Treatment Strategies for Advanced Endometrial Cancer According to Molecular Classification
by Valentina Tuninetti, Alberto Farolfi, Chiara Rognone, Daniela Montanari, Ugo De Giorgi and Giorgio Valabrega
Int. J. Mol. Sci. 2024, 25(21), 11448; https://doi.org/10.3390/ijms252111448 - 24 Oct 2024
Viewed by 834
Abstract
The management of advanced endometrial cancer (EC) has changed in the last few years due to the introduction of a new molecular classification and the approval of immunotherapy. For a long time, carboplatin plus paclitaxel was considered the standard treatment for first-line advanced [...] Read more.
The management of advanced endometrial cancer (EC) has changed in the last few years due to the introduction of a new molecular classification and the approval of immunotherapy. For a long time, carboplatin plus paclitaxel was considered the standard treatment for first-line advanced EC, since the approval of the combination of chemotherapy plus immunotherapy. For patients with recurrent EC, with previous platinum-based chemotherapy, single-agent immunotherapy or in combination with tyrosine-kinase inhibitor (TKI) has been approved according to mismatch repair status. Ongoing trials are exploring the possibility of a chemo-free future for mismatch repair-deficient (dMMR) EC and new molecular targets are under investigation. The treatment paradigm for advanced EC has shifted from standard chemotherapy for all to a more personalized approach. The aim of this review is to provide an updated therapeutic landscape for the management of patients with advanced/metastatic EC according to their disease history and molecular biology. Full article
Show Figures

Figure 1

Back to TopTop